the treatment could help thousands of people across the world to regain and retain some of their sight.

The FINANCIAL -- Injecting a gene therapy vector into one eye of someone suffering from LHON, the most common cause of mitochondrial blindness, significantly improves vision in both eyes, scientists have found. In a landmark phase 3 clinical trial, the international team, coordinated